



Effective Date:
Monday, July 09, 2012

New Tests and Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, July 09, 2012

New Tests - Tests recently added to the NMS Labs test menu. *New Tests are effective immediately.*

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.



Effective Date:
Monday, July 09, 2012

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
1275B	Clonidine, Blood								•	
1275SP	Clonidine, Serum/Plasma								•	
7657U	Cortisone Metabolites Panel, Urine (Research Use Only-RUO)		•							
7307SL	DNA Analysis, Half Profile									•
2917U	Dextromethorphan and Metabolite Ratio, Urine				•					
8079B	Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Blood (Forensic)						•			
8079U	Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Urine (Forensic)						•			
54022B	Drug Impaired Driving/DRE Toxicology Opiates (Low Dose) - Free (Unconjugated) Confirmation, Blood						•			
54022U	Drug Impaired Driving/DRE Toxicology Opiates (Low Dose) - Total (Conjugated/Unconjugated) Confirmation, Urine						•			
4025SP	Ezogabine and Metabolite, Serum/Plasma	•								
2466SP	Isotretinoin, Serum/Plasma (Retest)									•



New Tests and Test Updates

New Tests

4025SP	Ezogabine and Metabolite, Serum/Plasma	Effective Immediately
---------------	---	------------------------------

Scope of Analysis: Ezogabine [LC-MS/MS], N-Acetyl Ezogabine [LC-MS/MS]
 Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
 Purpose: Therapeutic Drug Monitoring
 Category: Antiepileptic, Anticonvulsant
 Specimen Requirements: 1 mL Serum or Plasma
 Minimum Volume: 0.4 mL
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Specimen Container: Plastic container (preservative-free)
 Transport Temperature: Refrigerated
 Light Protection: Not Required
 Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: 1 day(s)
 Refrigerated: 14 day(s)
 Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday 3 days (after set-up)
 CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Ezogabine Potiga; Retigabine; Trobalt	ng/mL	20	The optimized effective dose is 600 to 1200 mg daily. Ezogabine exhibits a linear pharmacokinetic profile between 600 - 1200 mg. Ezogabine is rapidly absorbed with a median time to maximum blood levels between 30 minutes to 2 hours. Patients titrated from 200 - 700 mg daily over a 15 day period had mean maximum plasma concentrations (Cmax +/- SD) of 1593 +/- 198 ng/mL. Administration of ezogabine at therapeutic doses may increase digoxin serum concentrations. Patients using ezogabine and digoxin should also have their digoxin levels monitored.
N-Acetyl Ezogabine AWD21-360; Ezogabine Metabolite	ng/mL	20	Formed by N-acetylation of ezogabine and is pharmacologically less active as compared to ezogabine. Patients titrated from 200 - 700 mg daily over a 15 day period had mean maximum plasma concentrations of (Cmax +/- SD) 874 +/- 75 ng/mL. Administration of ezogabine at therapeutic doses may increase digoxin serum concentrations. Patients using ezogabine and digoxin should also have their digoxin levels monitored.



New Tests and Test Updates

Test Changes

1275B Clonidine, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (83789): Clonidine
Method (CPT Code)

Compound Name	Units	Reference Comment
Clonidine	ng/mL	Immediate-release, oral: 0.50 - 2.0 ng/mL, 2 hours after administration; Sustained-release, patch: 0.20 - 2.0 ng/mL, at steady-state; Sustained-release, oral: 0.20 - 0.27 ng/mL, 6.8 +/- 3.6 hours after a 0.1 mg single dose in healthy fed adults; children receive higher doses on a mg/kg basis. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

1275SP Clonidine, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (83789): Clonidine
Method (CPT Code)

Compound Name	Units	Reference Comment
Clonidine	ng/mL	Immediate-release, oral: 0.50 - 2.0 ng/mL, 2 hours after administration; Sustained-release, patch: 0.20 - 2.0 ng/mL, at steady-state; Sustained-release, oral: 0.20 - 0.27 ng/mL, 6.8 +/- 3.6 hours after a 0.1 mg single dose in healthy fed adults; children receive higher doses on a mg/kg basis.

7657U Cortisone Metabolites Panel, Urine (Research Use Only-RUO)

Summary of Changes: Test Name was changed.

2917U Dextromethorphan and Metabolite Ratio, Urine

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.



New Tests and Test Updates

Test Changes

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8079B Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Blood (Forensic)

Summary of Changes: Scope of Analysis was changed.
Morphine - Free was removed.

Scope of Analysis: LC-MS/MS (80100): Hydromorphone - Free, Naltrexone - Free, Buprenorphine - Free, Norbuprenorphine - Free, Butorphanol - Free, Nalbuphine - Free, Naloxone - Free

8079U Drug Impaired Driving/DRE Toxicology Low Dose Opiates Add-On, Urine (Forensic)

Summary of Changes: Scope of Analysis was changed.
Morphine - Total was removed.

Scope of Analysis: LC-MS/MS (80100): Hydromorphone - Total, Naltrexone - Total, Buprenorphine - Total, Norbuprenorphine - Total, Butorphanol - Total, Nalbuphine - Total, Naloxone - Total

54022B Drug Impaired Driving/DRE Toxicology Opiates (Low Dose) - Free (Unconjugated) Confirmation, Blood

Summary of Changes: Scope of Analysis was changed.
Morphine - Free was removed.

Scope of Analysis: LC-MS/MS (83925): Hydromorphone - Free, Naltrexone - Free, Buprenorphine - Free, Norbuprenorphine - Free, Butorphanol - Free, Nalbuphine - Free, Naloxone - Free

54022U Drug Impaired Driving/DRE Toxicology Opiates (Low Dose) - Total (Conjugated/Unconjugated) Confirmation, Urine

Summary of Changes: Scope of Analysis was changed.
Morphine - Total was removed.

Scope of Analysis: LC-MS/MS (83925): Hydromorphone - Total, Naltrexone - Total, Buprenorphine - Total, Norbuprenorphine - Total, Butorphanol - Total, Nalbuphine - Total, Naloxone - Total



Effective Date:

Monday, July 09, 2012

New Tests and Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
7307SL	DNA Analysis, Half Profile	7300SL - DNA Analysis, Full Profile
2466SP	Isotretinoin, Serum/Plasma (Retest)	No Alternate Tests Available